Buscar
Mostrando ítems 1-10 de 91
Trastornos autonómicos en enfermedad de Parkinson
(Sociedad Médica de Santiago, 2011)
Impairment of agonist-induced M2 muscarinic receptor activation by autoantibodies from chagasic patients with cardiovascular dysautonomia
(Academic Press Inc Elsevier Science, 2020-03)
Previous studies showed that circulating autoantibodies against M2 muscarinic receptors (anti-M2R Ab) are associated with decreased cardiac parasympathetic modulation in patients with chronic Chagas disease (CD). Here we ...
State-of-the-art Pharmacotherapy for Autonomic Dysfunction in Parkinson's Disease
(Informa Healthcare, 2020-03)
Introduction: Autonomic dysfunction is one of the most frequent and disabling non-motor symptoms of Parkinson’s disease (PD). It includes, among others, orthostatic hypotension (OH), sialorrhea, constipation, erectile ...
Hypermobility and Ehlers-Danlos syndromes: Clinical aspects and patient's quality of life
(Centro de Estudios Académicos en Neuropsicología, 2016)
There is an urgent need to increase the Joint Hypermobility Syndrome (JHS) awareness, that for most authors is the same as the Ehlers-Danlos Hypermobility type (formerly called EDS type III) that is a congenital, very ...
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Neurological Entity?
(Kaunas Univ Medicine & Vilnius Univ, 2021-09-27)
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disorder of unknown physiopathology with multisystemic repercussions, framed in ICD-11 under the heading
of neurology (8E49). There is no specific test to ...
Clinical Heterogeneity in ME/CFS: A Way to Understand Long-COVID19 Fatigue
(Frontiers Media, 2021-10)
The aim of present paper is to identify clinical phenotypes in a cohort of patients affected of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Ninety-one patients and 22 healthy controls were studied with the following ...